Cardiology

The IND submission for VERVE-102 was supported by interim data from the dose-escalation portion of the ongoing Heart-2 Phase 1b clinical trial.

Our top 5 headlines featured new migraine guidelines, the benefit of automated insulin delivery for type 2 diabetes, and 3 key FDA decisions.

Bhatt previews 3 late-breaking clinical trials being presented at this year's American College of Cardiology Annual Scientific Sessions.

The approval expands the indication for vutrisiran, which becomes the first therapeutic approved by the FDA for the treatment of ATTR-CM.

AID technology outperformed CGM alone to reduce HbA1c, without increasing hypoglycemia, in adults with insulin-treated type 2 diabetes.

Initiation of the MOMENTUM clinical trial will explore the prevalence of endogenous hypercortisolism in patients with resistant hypertension.

If approved, this indication targets the treatment of adult patients with heart failure with a left ventricular ejection fraction of ≥40%.

In this episode, hosts discuss the impact of recently launched direct, cash pay options for people using semaglutide and tirzepatide.

Our top 5 headlines featured an oral drug delivering 16% weight loss, notable blood pressure reductions from a hypertension treatment, and 3 key FDA decisions.

Food insecurity remained associated with incident CVD after adjustment for socioeconomic factors among participants in the 2000-2020 CARDIA study period.

The novel controlled metabolic accelerator significantly reduced fat-specific body weight but showed no improvements in exercise capacity over 19 weeks.

A study of 3 large US cohorts found a higher intake of butter was linked to greater mortality rates, while plant-based oil intake lowered total mortality.

The regulatory agency granted 510(k) clearance to Caristo Diagnostics' image analysis software to aid in coronary artery disease diagnosis.

Fonarow describes a revised classification of glucose levels that breaks down the normal range into lower and higher levels of associated cardiovascular risk.

Topline data from the pivotal Launch-HTN and Advance-HTN trials met primary endpoints, supporting lorundrostat for uncontrolled or resistant hypertension.

The regulatory agency accepted the BLA's filing and assigned a target action date of August 31, 2025.

The agency approved the first generic of the anticoagulant rivaroxaban to lower the risk of cardiovascular and thromboembolic events in adults with CAD and PAD.

Marking the first stroke medicine approved in nearly 30 years, the single five-second intravenous bolus provides faster administration than the standard of care.

The February 2025 cardiology review covers pipeline updates in lipid management, key regulatory acceptances and approvals, and shifting ASCVD trial endpoints.

This FDA News Month in Review provides a round-up of regulatory decisions from February 2025.

New data from the REDUCE-IT trial suggests icosapent ethyl offers benefit even among those with LDL-C less than 55 mg/dL.

Finerenone reduces outpatient worsening HF in patients with mildly reduced or preserved ejection fraction in a secondary analysis of FINEARTS-HF.

In this Diabetes Dialogue segment, hosts discussed the strengths of trial diversity and HbA1c reductions with automated insulin delivery in type 2 diabetes.

With this FDA approval, chenodiol tablets become the first approved drug to treat CTX, a rare lipid storage disease.

The US supply of semaglutide and semaglutide 2.4 mg now meets or exceeds current and projected demand, ending the long-running shortages of these blockbuster drugs.